ArticleThe oncologist2019

Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.

Maria Vittoria Dieci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.